Akeso, Summit hail ivonescimab’s biliary tract cancer win in China-only Phase 3 trialnews2026-08-26T11:02:44+00:00August 26th, 2026|Endpoints News|
ARCH and Population Health join China blitz with Haisco dealnews2026-08-25T14:15:05+00:00August 25th, 2026|Endpoints News|
China IIT deaths prompt lawmakers to request FDA clampdownnews2026-08-21T11:00:51+00:00August 21st, 2026|Endpoints News|
Three deaths in China shake trust in its speedy clinical trial systemnews2026-08-20T18:05:41+00:00August 20th, 2026|Endpoints News|
Bristol Myers’ partner Biokin says bispecific ADC clears fourth cancer trial in Chinanews2026-08-19T11:05:05+00:00August 19th, 2026|Endpoints News|
Exclusive: Third death revealed in China’s popular but opaque trialsnews2026-08-18T14:25:50+00:00August 18th, 2026|Endpoints News|
Summit, Akeso’s ivonescimab shows smaller benefit with longer follow-up in Chinanews2026-08-17T14:48:39+00:00August 17th, 2026|Endpoints News|
Biogen’s monoclonal antibody felzartamab wins first global approval in Chinanews2026-08-14T17:11:14+00:00August 14th, 2026|Endpoints News|
Post-Hoc: Rewatch the Boston edition of our China Biotech Debatenews2026-08-12T15:43:32+00:00August 12th, 2026|Endpoints News|
Boulevard Bio dreams big in immunology with $65M, sights on Vera’s IgAN drugnews2026-08-12T10:30:11+00:00August 12th, 2026|Endpoints News|
